Page 6 Medical & Healthcare Expert Guide 2019
P. 6
Expert Guide |
Litigation & Dispute Resolution 2018
6
First identified in 1906, leading experts in science and medicine have
been thwarted in their efforts to find a cure for Alzheimer’s disease
for more than a century. Today, the progressive neurodegenerative
disorder is the only leading cause of death that is still on the rise
with a total number of affected individuals predicted to increase to
13 million in the United States and over 100 million worldwide by
2050. It is without doubt one of the biggest public health problems
of the 21 century.
st
Founded in 2006, Cenna Biosciences Inc. has made one of the
biggest breakthroughs to date in the on-going quest to find a cure
for this deadly disease. Corporate LiveWire recently spoke with Dr.
Nazneen Dewji, President & CEO of Cenna Biosciences Inc., to find
out more about how this innovative company has set its sights
on making a significant impact in both treatment and prevention
through new therapeutic approaches.
What is Alzheimer’s disease and why is it a
growing concern around the world?
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder that results in memory loss and a decline in mental function
over time, eventually resulting in death. It is the most common form
of dementia, making up between 60-80% of all dementia cases.
Age is a risk factor. The disease affects one in 10 people over the age
of 65, one in two by age 90 . With improved nutrition and health
care, we are all living very much longer these days and most of us
in the developed world can expect to live to be 90. The developing
world is also catching up with longer life spans and in the coming
years will be the areas of the world with the greatest increase in
numbers of people affected with AD. The financial and emotional
burden of caring for people with AD is enormous. That is the reason
why it is such a growing concern around the world.
Tackling Alzheimer’s Disease
An Interview with Dr. Nazneen Dewji
(President & CEO of Cenna Biosciences Inc.)
Dr. Nazneen Dewji is the President and CEO of Cenna Biosciences Inc. in La Jolla, CA
and an Associate Adjunct Professor of Medicine at the University of California, San
Diego. Nazneen was born in Tanzania and raised in England. She was educated at the
University of London, where she earned her B.Sc. (Hons.) and Ph.D. degrees. In 1986
she accepted a faculty position in the department of Medicine at UCSD. Since then
she has worked on the molecular and cellular mechanisms in Alzheimer’s disease
(AD). The discoveries made in her laboratory at UCSD support the development of
new disease-modifying drug candidates for the treatment of AD. These are currently
being developed at Cenna Biosciences Inc, a start-up company that she, along with
her colleague the late Dr. S. J. Singer, founded in 2006. Cenna’s proprietary technology
addresses the underlying cause of the disease, the inappropriate deposition of
the toxic species, ß-amyloid (Aß). The Company has developed novel targets and
is developing several lead peptide and small molecule compounds as disease-
modifying drug candidates for the treatment of AD.
About Dr. Nazneen Dewji
One
in
10
people over the age of
65
ALZHEIMER’S AFFECTS
One
in
two
people over the age of
90
Litigation & Dispute Resolution 2018
6
First identified in 1906, leading experts in science and medicine have
been thwarted in their efforts to find a cure for Alzheimer’s disease
for more than a century. Today, the progressive neurodegenerative
disorder is the only leading cause of death that is still on the rise
with a total number of affected individuals predicted to increase to
13 million in the United States and over 100 million worldwide by
2050. It is without doubt one of the biggest public health problems
of the 21 century.
st
Founded in 2006, Cenna Biosciences Inc. has made one of the
biggest breakthroughs to date in the on-going quest to find a cure
for this deadly disease. Corporate LiveWire recently spoke with Dr.
Nazneen Dewji, President & CEO of Cenna Biosciences Inc., to find
out more about how this innovative company has set its sights
on making a significant impact in both treatment and prevention
through new therapeutic approaches.
What is Alzheimer’s disease and why is it a
growing concern around the world?
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder that results in memory loss and a decline in mental function
over time, eventually resulting in death. It is the most common form
of dementia, making up between 60-80% of all dementia cases.
Age is a risk factor. The disease affects one in 10 people over the age
of 65, one in two by age 90 . With improved nutrition and health
care, we are all living very much longer these days and most of us
in the developed world can expect to live to be 90. The developing
world is also catching up with longer life spans and in the coming
years will be the areas of the world with the greatest increase in
numbers of people affected with AD. The financial and emotional
burden of caring for people with AD is enormous. That is the reason
why it is such a growing concern around the world.
Tackling Alzheimer’s Disease
An Interview with Dr. Nazneen Dewji
(President & CEO of Cenna Biosciences Inc.)
Dr. Nazneen Dewji is the President and CEO of Cenna Biosciences Inc. in La Jolla, CA
and an Associate Adjunct Professor of Medicine at the University of California, San
Diego. Nazneen was born in Tanzania and raised in England. She was educated at the
University of London, where she earned her B.Sc. (Hons.) and Ph.D. degrees. In 1986
she accepted a faculty position in the department of Medicine at UCSD. Since then
she has worked on the molecular and cellular mechanisms in Alzheimer’s disease
(AD). The discoveries made in her laboratory at UCSD support the development of
new disease-modifying drug candidates for the treatment of AD. These are currently
being developed at Cenna Biosciences Inc, a start-up company that she, along with
her colleague the late Dr. S. J. Singer, founded in 2006. Cenna’s proprietary technology
addresses the underlying cause of the disease, the inappropriate deposition of
the toxic species, ß-amyloid (Aß). The Company has developed novel targets and
is developing several lead peptide and small molecule compounds as disease-
modifying drug candidates for the treatment of AD.
About Dr. Nazneen Dewji
One
in
10
people over the age of
65
ALZHEIMER’S AFFECTS
One
in
two
people over the age of
90
